Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer

International Journal of Cancer

Volumn 121, Issue 11, 2007, Pages 2532-2538

  Garcia Closas, Montserrat ^a   Kristensen, Vessela ^b,c   Langerød, Anita ^b   Qi, Ying ^a   Yeager, Meredith ^a   Burdett, Laurie ^a   Welch, Robert ^a   Lissowska, Jolanta ^d   Peplonska, Beata ^e   Brinton, Louise ^a   Gerhard, Daniela S ^a   Gram, Inger Torhild ^f   Perou, Charles M ^g   Børresen Dale, Anne Lise ^b,c   Chanock, Stephen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^f UNIVERSITY OF TROMSØ   (Norway)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Polymorphisms; TP53

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

3' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; ATP1B2 GENE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; NORWAY; POLAND; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR SUPPRESSOR GENE; WDR79 GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CATION TRANSPORT PROTEINS; CELL ADHESION MOLECULES, NEURONAL; ESTROGENS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; NORWAY; ODDS RATIO; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; RISK ASSESSMENT; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VARIATION (GENETICS);

EID: 35649002434     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22985     Document Type: Article

References (35)

1. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:92-300.
2. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990;250:1233-8.
3. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-1100.
4. Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res 1991;19:4747-52.
5. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
6. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 1996;93:15335-40.
7. Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 2006;98:1382-96.
8. Campbell IG, Eccles DM, Dunn B, Davis M, Leake V. p53 polymorphism in ovarian and breast cancer. Lancet 1996;347:393-4.
9. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17:1313-16.
10. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 1998;18:2095-9.
11. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 2002;12:269-72.
12. Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski KM, Berstein LM, Hanson KP, Togo AV, Imyanitov EN. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 2003;103:431-3.
13. Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 2004;25:1568-73.
14. Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K Rotter V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol 1995;14:983-90.
15. Mavridou D, Gomall R, Campbell IG, Eccles DM. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer 1998;77:676-7.
16. Weston A, Wolff MS, Morabia A. True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet 1998; 102:153-4.
17. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 1997;6:105-112.
18. Langerød A, Burdette LYM, Llaca V, Presswalla S, Gerhadt D, Tarazona-Santos , Garcia-Rossi D, Lønning PE, Kristensen VN, Perou C, Børresen-Dale A-L, Chanock SJ. Pattern of genetic variation in the TP53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat, in press.
19. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 1997;181:140-5.
20. Langerød A, Zhao H, Borgan O, Nesland JM, Bukholm IK, Ikdal T, Kåresen R, Børresen-Dale A-L, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res, 2007;9(3):R30.
21. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993;68:540-8.
22. Edvardsen H, Kristensen VN, Alnæs GIG, Bøhn M, Erikstein B, Heiland Ås, Børresen-Dale A-L, Fosså SD. Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cuteaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1163-71.
23. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469-78.
24. Naume B, Zhao H, Synnestvedt M, Borgen E, Strømberg M, Russnes HG, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Lindgjærde OC, Børresen-Dale A-L, et al. Presence of micrometastasis in bone marrow is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol, in press.
25. Gram IT, Bremnes Y, Ursin G, Maskarinec G, Bjurstam N, Lund E. Percentage density, Wolfe's and Tabar's mammographic patterns: agreement and association with risk factors for breast cancer. Breast Cancer Res 2005;7:R854-R861.
26. Helle SI, Ekse D, Holly JM, Lonning PE. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. J Steroid Biochem Mol Biol 2002;81:95-102.
27. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006;95:123-9.
28. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, Sicotte H, Staats B, Acharya M, Crenshaw A, Eckert A, Puri V, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617-D621.
29. Schaid DJ. Evaluating associations of haplotypes with traits. Genet Epidemiol 2004;27:348-64.
30. Carey LA, Perou CM, Livasy CA, Dressier LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
31. Laitinen J, Rakkolainen T, Holtta E. Vectorettes for long chromosome walking in genomic DNA of the human p53 gene. Biotechniques 2004;37:674-6, 678.
32. Smith TF, Gaitatzes C, Saxena K, Neer EJ. The WD repeat: a common architecture for diverse functions. Trends Biochem Sci 1999;24:181-5.
33. Spargue BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM. Genetic variation in TP53 and risk of breast cancer in a population-based case-control study. Carcinogenesis, 2007, Apr 21; [Epub ahead of print].
34. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54.
35. Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer 1999;81:179-183.